Articles tagged with Breast Cancer Cells
Research using genetic variants as proxies for physical activity levels found a link between higher activity and lower invasive breast cancer risk. A higher overall level of genetically predicted physical activity was associated with a 41% lower risk of invasive breast cancer.
Researchers have developed a new method for 3D cell culture that accurately quantifies how breast cancer cells generate forces to spread within tissue. This study provides more accurate computational data on cellular forces during invasion by breast cancer cells, which may lead to more efficient and personalized drug development.
A study from Lund University found that Caveolin-1 protein levels in surrounding tumour tissue affect breast cancer prognosis. The study suggests that this protein could be used as a marker for precise prognosis and treatment choice.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.
Researchers at Dartmouth Cancer Center developed a new approach for detecting and quantifying tumor heterogeneity in breast cancer. High levels of heterogeneity are linked to poor patient outcomes, while specific proteins regulate its extent. The study aims to utilize this approach in therapeutic decision-making.
A team of researchers developed a clonal barcoding approach to track live cancer cells, enabling the detection and isolation of precise clones responsible for tumor formation and early metastases. This technology has the potential to be applied to other cell-based studies, providing valuable insights into biological processes.
Researchers analyzed germline variants in breast cancer patients to identify their role in metastasis development. The study found that host genetic makeup contributes to metastasis through dysregulation of gene expression, promoting the dispersion of metastatic seeds and establishing a conducive environment for their growth.
Researchers have uncovered how tissue stiffness determines cell positioning and regulates cell migration in various types of cancer, including brain tumors and breast cancer. The study provides new possibilities for stopping and directing cancer cell migration.
Abemaciclib, a CDK4 & 6 inhibitor, showed profound inhibition of cell proliferation and triggered senescence and apoptosis in breast cancer cells. Continuous dosing provided sustained inhibition with irreversible effects through apoptosis, supporting the differentiated safety and efficacy profile.
Research from RCSI University of Medicine and Health Sciences found a link between high von Willebrand Factor levels and poorer breast cancer outcomes. High levels in the bloodstream can increase the risk of life-threatening blood clots and cancer spread in patients.
Researchers at LSU Health Sciences Center have discovered a novel combination therapy that effectively treats chemo-resistant triple-negative breast cancer. The treatment combines two existing FDA-approved drugs, ceritinib and enzalutamide, to target the growth of cancer cells, showing promise for improving treatment outcomes.
Researchers at Johns Hopkins Kimmel Cancer Center developed a targeted immunotoxin that delivers into breast ducts, eliminating visible and invisible precancerous lesions in laboratory studies. The treatment showed strong cancer-killing effects in all cell lines and was well-tolerated in mouse models.
A new study found that parabens increase the growth, invasion, and expression of genes linked to cancer in breast cancer cells from Black women. This effect was more pronounced in Black cell lines compared to white cell lines.
A new genetic study published in Nature Genetics found that roughly one in five invasive breast cancers following ductal carcinoma in situ (DCIS) are genetically unrelated to the original DCIS. The findings provide a deeper understanding of DCIS biology and suggest that DCIS should be considered a risk factor for the development of inv...
A recent study identified 34 novel genes that contribute to endocrine resistance in breast cancer using dynamic gene expression analysis. The researchers found that these genes are differentially expressed in both estrogen receptor-positive and triple-negative breast cancers, suggesting shared genetic mechanisms underlying resistance d...
Researchers at Massachusetts General Hospital discovered a novel immunotherapy mechanism that uses CD4+ T helper 2 cells to suppress breast cancer development. These cells force breast cancer cells to revert to benign breast gland cells, providing new insights into the treatment of this disease.
A compound called ERX-41 has been shown to kill a range of hard-to-treat cancer types, including breast and ovarian cancers, by targeting a previously unexploited vulnerability. This could lead to new drugs being developed to fight these cancers, which currently have few effective treatments.
Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.
Research describes how breast cancer cells impair pancreatic islet function to suppress insulin production, leading to diabetes and increased tumor growth. The study identifies microRNA-122 as a key player in this process.
A new study found that crown-like structures surrounding breast tumors in overweight and obese patients can hinder their response to therapy. Researchers identified a potential molecular biomarker, CD32B, which is associated with poorer treatment outcomes.
A recent study published in Breast Cancer Research suggests that self-reported male infertility may be associated with an increased risk of invasive breast cancer. The researchers conducted a case-control study among 1,998 males diagnosed with breast cancer, comparing them to 1,597 control males without blood relatives. The study found...
Researchers developed PASTE, a method to analyze spatial transcriptomics data in three dimensions, enabling biologists to better understand cell environments and identify rare cell types. The technique can integrate information from multiple tissue slices, providing a more complete picture of gene expression within tissues.
Researchers found that targeting both tumor and lymph node microenvironments with nanomedicine improves treatment response for metastatic triple negative breast cancer. Long-term tumor remission was achieved in mice models using nanoparticles to deliver immune-modulating drugs.
Breast cancer cells accumulate intracellular lipid droplets in acidic environments, leading to poor outcomes and disease progression. Targeting the acid-sensing receptor OGR1 may inhibit stress responses and cell growth.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
Researchers at Mount Sinai have discovered a previously unknown mechanism by which not-yet-malignant breast cancer cells can travel to other organs and 'turn on' to become metastatic. The study identified potential diagnostic biomarkers, including the transcription factor NR2F1, that could help predict relapse.
Researchers at Georgetown University Medical Center have discovered new genetic and cellular factors that can determine breast cancer recurrence. The study's findings have the potential to improve treatment choices and screening methods, and may also benefit women who have not had breast cancer.
A team of biologists identified a protein involved in the spread of breast cancer to bones. The discovery confirms the importance of cellular plasticity during the metastatic process and could lead to new treatments. ZEB1, a protein that increases cell plasticity, was found to direct cells with metastatic characteristics to bones.
A mutated gene in more than 20% of breast cancer recurrences promotes metastasis and resistance to hormone therapy. Researchers identify potential vulnerabilities, leading to the development of personalized treatment approaches.
Researchers at Weill Cornell Medicine discovered that cancer cells suppress a key enzyme in propionate metabolism, increasing production of methylmalonic acid (MMA) and causing cells to become more aggressive. This metabolic change may hold the key to understanding how tumors metastasize and developing novel therapies.
Researchers identified genes and epigenomic marks that enable cancer cells to resist chemotherapy. By inhibiting these marks, epi-drugs can restore treatment sensitivity. Future clinical trials aim to adapt this concept for human use.
The University of Cincinnati researcher Xiaoting Zhang has been awarded a five-year grant renewal to continue his genetic driver study of breast cancer and potential therapeutic targets. Zhang's team discovered that the gene MED1 functions as a co-driver with HER2 in promoting tumor growth, spread, and treatment resistance.
Researchers have created a biobank of breast cancer organoids from 87 patient tumor samples, including nearly half that are 'triple negative', an aggressive form of the disease. The biobank allows scientists to test specific drugs on those cancers in a dish, potentially leading to better treatment options.
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
Researchers identify two genes, GLI1 and Notch1, responsible for aggressive growth and spread of triple negative breast cancers in African American women. A combination approach using inhibitors and chemotherapy agents significantly inhibits tumor growth and metastasis.
A team from UNIGE has identified a potential target for restoring the efficacy of standard breast cancer treatment. The loss of SPRED2 protein leads to tumor proliferation even with tamoxifen treatment. Combining tamoxifen with an inhibitor of estrogen-independent cell activation may be promising for resistant patients.
A study found that women with DCIS often face uncertainty about their cancer status and the appropriateness of treatment. The research highlights the need for improved communication between clinicians and patients to address these concerns and promote overall well-being.
Researchers at the University of Houston have identified a new biomarker, NPY1R, that predicts therapy outcome and has potential as a drug target in estrogen receptor-positive breast cancer. The study found that NPY1R expression is associated with favorable outcomes in Luminal A subtype breast cancer, but declines in resistant cases.
Researchers found significant molecular differences in DNA repair genes and cellular signals controlling cell growth between healthy and tumor tissue of Black and white women. These differences may lead to improved treatment strategies for ER+ breast cancer, including earlier use of CDK inhibitors.
Researchers have discovered live cells in human breast milk, which may provide insights into breast cancer development and improve breastfeeding outcomes. The study, led by Dr. Alecia-Jane Twigger, found that these living cells can be used to study mammary gland function and identify potential early indicators of future breast cancer.
Researchers have found that depleting copper levels in the body can greatly reduce the ability of cancer cells to metastasize, including aggressive breast cancer. The discovery provides hope for developing more effective treatments for high-risk triple-negative breast cancer.
A new blood test developed at Hebrew University of Jerusalem detects immune and inflammatory activity in tissues by monitoring circulating DNA fragments. This method provides accurate information about immune processes in remote tissues, removing the need for invasive measures.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a novel way to classify breast cancers into 12 distinct biological groups using both genetic and pathologic data. This classification method has the potential to aid future research efforts and enable faster translation of molecular findings into clinical use.
Researchers used mathematical models and genetic analysis to identify key gene regulators that can switch aggressive basal-like breast cancer into less dangerous luminal-A. This approach could lead to novel therapeutic targets for treating many other types of cancer.
Researchers discovered that pregnancy triggers the activation of Natural Killer T (NKT) cells to prevent breast cancer. After pregnancy, breast epithelial cells produce a specific protein called CD1d, which attracts NKT cells to monitor and eliminate potential cancer cells.
Moffitt researchers have developed a HER3-specific dendritic cell cancer vaccine that delays tumor growth and prolongs survival in mouse models. The vaccine targets the HER3 protein, which is involved in the growth and spread of many different cancer types.
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
Researchers at Brigham and Women's Hospital discovered that cancer cells can disarmed the immune system by forming nanotubes that pull out mitochondria from immune cells. This new mechanism gives a target to go after, leading to potential new combinations of therapies for improving cancer immunotherapy outcomes.
A new study found that tumors with one mutant copy of the PIK3CA gene tend to have lower PI3K activity, while those with two or more copies often have higher PIK3α activity, leading to more aggressive tumors and poorer prognosis. The research also discovered a counterintuitive relationship between PI3K mutations, PI3K activity, and ste...
A Johns Hopkins-led study found that leptin cancels out the effects of Tamoxifen, making it ineffective for obese patients with breast cancer. Researchers suggest that interventions targeting leptin or Med1 may improve Tamoxifen's success in this group.
Researchers in mice found that chemotherapy enhances cancer's spread by making blood vessel walls more receptive, allowing cancer cells to latch on. The study shows how a chemo drug like cyclophosphamide alters non-cancer cells' properties, facilitating the cancer cells' attachment and progression.
Cancer cells can change their shape and migration techniques to invade different types of tissue, a process that plays a huge role in prognosis. The study found that cells switch between migration programs more often than thought, allowing them to adapt to heterogeneous environments.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.